- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 579-593 of
973 results
2106 Exhibit: EX2106 Ozempic FDA Approval Letter Dec 15, 2017
Document
IPR2023-00724, No. 2106 Exhibit - EX2106 Ozempic FDA Approval Letter Dec 15, 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1060 Exhibit: WO193
Document
IPR2023-00724, No. 1060 Exhibit - WO193 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1312 Exhibit: Exhibit 1312 Redacted Jensen Dep
Document
IPR2023-00724, No. 1312 Exhibit - Exhibit 1312 Redacted Jensen Dep (P.T.A.B. Jun. 21, 2024)
|
|
Cite Document
2541 Exhibit: EX2541 Dr Reddy’s Laboratories, Ltd’s and Dr Reddy’s Laboratories...
Document
IPR2023-00724, No. 2541 Exhibit - EX2541 Dr Reddy’s Laboratories, Ltd’s and Dr Reddy’s Laboratories, Inc’s Stipulation Concerning Invalidity Grounds, In re Ozempic Semaglutide Patent Liti...
|
|
Cite Document
2538 Exhibit: EX2538 Excerpt of Opening Expert Report of Dr Paul Dalby Regardin...
Document
IPR2023-00724, No. 2538 Exhibit - EX2538 Excerpt of Opening Expert Report of Dr Paul Dalby Regarding Invalidity of US Patent No 10,335, 462, In re Ozempic Semag lutide Patent Litigation, N...
|
|
Cite Document
2353 Exhibit: EX2353 Mayo Clinic, “Hyperglycemia in diabetes – Symptoms causes...
Document
IPR2023-00724, No. 2353 Exhibit - EX2353 Mayo Clinic, “Hyperglycemia in diabetes – Symptoms causes,” httpswwwmayoclinicorgdiseases conditionshyperglycemiasymptoms causessyc 2037...
|
|
Cite Document
2416 Exhibit: EX2416 US Food Drug Administration, Orange Book Approved Drug ...
Document
IPR2023-00724, No. 2416 Exhibit - EX2416 US Food Drug Administration, Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 208335 (P.T.A.B. Jan. 17, 2...
|
|
Cite Document
2414 Exhibit: EX2414 US Food Drug Administration, DrugsFDA, Tradjenta®
Document
IPR2023-00724, No. 2414 Exhibit - EX2414 US Food Drug Administration, DrugsFDA, Tradjenta® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2508 Exhibit: EX2508 Novo Nordisk, Financial report for the period 1 January 2021...
Document
IPR2023-00724, No. 2508 Exhibit - EX2508 Novo Nordisk, Financial report for the period 1 January 2021 to 30 September 2021 Nov 3, 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2413 Exhibit: EX2413 US Food Drug Administration, Orange Book Approved Drug ...
Document
IPR2023-00724, No. 2413 Exhibit - EX2413 US Food Drug Administration, Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 206081 (P.T.A.B. Jan. 17, 2...
|
|
Cite Document
2478 Exhibit: EX2478 Chen, J, Blockbuster Drug What it is, How it works, Investope...
Document
IPR2023-00724, No. 2478 Exhibit - EX2478 Chen, J, Blockbuster Drug What it is, How it works, Investopedia, httpswwwinvestopediacomtermsbblockbuster drugasp, last updated Sept 6, 2022 (P...
|
|
Cite Document
1115 Exhibit: Exhibit 1115 CDC Report
Document
IPR2023-00724, No. 1115 Exhibit - Exhibit 1115 CDC Report (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2506 Exhibit: EX2506 Novo Nordisk, Financial report for the period 1 January 2021...
Document
IPR2023-00724, No. 2506 Exhibit - EX2506 Novo Nordisk, Financial report for the period 1 January 2021 to 31 March 2021 May 5, 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2012 Exhibit: EX2012 Rossing, P, et al, “The rationale, design and baseline data of...
Document
IPR2023-00724, No. 2012 Exhibit - EX2012 Rossing, P, et al, “The rationale, design and baseline data of FLOW, a kidney outcomes trial with once weekly semaglutide in people with type 2 diabe...
|
|
Cite Document
3004 Exhibit: Ex 3004 Attorney Correspondence
Document
IPR2023-00724, No. 3004 Exhibit - Ex 3004 Attorney Correspondence (P.T.A.B. Jun. 18, 2024)
|
|
Cite Document
